Hercules Capital, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED SCHEDULE OF INVESTMENTS

CONSOLIDATED SCHEDULE OF INVESTMENTS £ in Thousands		9 Months Ended		12 Months Ended
CONSOLIDATED SCHEDULE OF INVESTMENTS £ in Thousands		Sep. 30, 2022 USD ($) shares		Dec. 31, 2021 USD ($) shares		Sep. 30, 2022 GBP (£) shares		Dec. 31, 2021 GBP (£) shares		Sep. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)
Investment Holdings [Line Items]
Investment cost		$ 2,869,469,000		$ 2,390,984,000
Investments at Fair Value		2,825,738,000		2,434,522,000
Equity
Investment Holdings [Line Items]
Investment cost		150,539,000	^[1]	142,219,000	^[2]
Investments at Fair Value		134,134,000		184,710,000
Warrant Investment
Investment Holdings [Line Items]
Investment cost		31,148,000	^[1]	27,147,000	^[2]
Investments at Fair Value		27,159,000		38,399,000
Investments in Securities [Member]
Investment Holdings [Line Items]
Investment cost	^[2]			2,388,952,000
Investments at Fair Value				2,432,708,000
Investment [Member]
Investment Holdings [Line Items]
Investment cost	^[2]			2,390,984,000
Investments at Fair Value				2,434,522,000
Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment cost	^[1]	3,139,000
Investments at Fair Value		3,046,000
Senior Secured
Investment Holdings [Line Items]
Investments at Fair Value		2,607,006,000		$ 2,156,709,000
Senior Secured \| Blue Sprig Pediatrics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment, Interest Rate, Paid in Kind				4.45%				4.45%
Total Investments Before Cash And Cash Equivalent [Member]
Investment Holdings [Line Items]
Investment cost	^[1],[3]	2,869,469,000
Investments at Fair Value		2,825,738,000
Total Investments with Cash and Cash Equivalents
Investment Holdings [Line Items]
Investment cost	^[1],[3]	2,894,469,000
Investments at Fair Value	^[3]	2,850,738,000
Total investments In Securities
Investment Holdings [Line Items]
Investment cost	^[1]	2,866,330,000
Investments at Fair Value		2,822,692,000
Cash and Cash Equivalents \| G S Financial Square Government Fund
Investment Holdings [Line Items]
Investment cost	^[1]	25,000,000
Investments at Fair Value		25,000,000
Money Market Funds [Member]
Investment Holdings [Line Items]
Investment cost	^[1],[3]	25,000,000
Investments at Fair Value	^[3]	25,000,000
Debt Investments
Investment Holdings [Line Items]
Investment cost		2,684,643,000	^[1]	$ 2,219,586,000	^[2]
Investments at Fair Value		2,661,399,000		2,209,599,000
Unsecured
Investment Holdings [Line Items]
Investments at Fair Value		54,393,000		52,890,000
Communications & Networking
Investment Holdings [Line Items]
Investments at Fair Value		101,094,000		105,490,000
Communications & Networking \| Equity
Investment Holdings [Line Items]
Investment cost	^[2]			1,230,000
Investments at Fair Value				6,260,000
Communications & Networking \| Warrant Investment
Investment Holdings [Line Items]
Investment cost		541,000	^[1]	418,000	^[2]
Investments at Fair Value		140,000		0
Communications & Networking \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment cost		98,596,000	^[1]	97,088,000	^[4]
Investments at Fair Value		100,954,000		99,230,000
Communications & Networking \| Aryaka Networks, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1]	123,000
Investments at Fair Value		$ 140,000
Investment, Acquisition Date	^[5]	Jun. 28, 2022
Shares \| shares		229,611				229,611
Communications & Networking \| Peerless Network Holdings, Inc. \| Equity
Investment Holdings [Line Items]
Investment cost	^[2]			1,230,000
Investments at Fair Value				$ 6,260,000
Shares \| shares				1,138,328				1,138,328
Communications & Networking \| Peerless Network Holdings, Inc. \| Equity \| Preferred Series A
Investment Holdings [Line Items]
Investment cost	^[2]			$ 1,230,000
Investments at Fair Value				$ 6,242,000
Investment, Acquisition Date	^[6]			Apr. 11, 2008
Shares \| shares				1,135,000				1,135,000
Communications & Networking \| Peerless Network Holdings, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]			$ 0
Investments at Fair Value				$ 18,000
Investment, Acquisition Date	^[6]			Oct. 21, 2020
Shares \| shares				3,328				3,328
Communications & Networking \| Spring Mobile Solutions, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 418,000	^[1]	$ 418,000	^[2]
Investments at Fair Value		$ 0		$ 0
Investment, Acquisition Date		Apr. 19, 2013	^[5]	Apr. 19, 2013	^[6]
Shares \| shares		2,834,375		2,834,375		2,834,375		2,834,375
Communications & Networking \| Senior Secured \| Aryaka Networks, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-07				2026-07
Investment, Basis Spread, Variable Rate	^[7]	3.25%				3.25%
Investment, Interest Rate, Floor	^[7]	6.75%				6.75%
Investment, Interest Rate, Paid in Kind	^[7]	1.05%				1.05%
Principal Amount	^[8],[9],[10]	$ 5,009,000
Investment cost	^{[1],[8],[9],[10]}	4,943,000
Investments at Fair Value	^[8],[9],[10]	$ 4,943,000
Communications & Networking \| Senior Secured \| Cytracom Holdings LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-02		2025-02		2025-02		2025-02
Investment, Basis Spread, Variable Rate		9.31%	^[7]	9.31%	^[11]	9.31%	^[7]	9.31%	^[11]
Investment, Interest Rate, Floor		10.31%	^[7]	10.31%	^[11]	10.31%	^[7]	10.31%	^[11]
Principal Amount		$ 8,933,000	^{[10],[12],[13]}	$ 9,000,000	^{[14],[15],[16]}
Investment cost		8,776,000	^{[1],[10],[12],[13]}	8,802,000	^{[4],[14],[15],[16]}
Investments at Fair Value		$ 8,728,000	^{[10],[12],[13]}	$ 8,725,000	^{[14],[15],[16]}
Communications & Networking \| Senior Secured \| Rocket Lab Global Services, LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2024-06		2024-06		2024-06		2024-06
Investment Interest Rate	^[11]			3.25%				3.25%
Investment, Basis Spread, Variable Rate		4.90%	^[7]	4.90%	^[11]	4.90%	^[7]	4.90%	^[11]
Investment, Interest Rate, Floor		8.15%	^[7]	8.15%	^[11]	8.15%	^[7]	8.15%	^[11]
Investment, Interest Rate, Paid in Kind		1.25%	^[7]	1.25%	^[11]	1.25%	^[7]	1.25%	^[11]
Interest Rate and Floor	^[11]			3.25%				3.25%
Principal Amount		$ 84,314,000	^{[9],[12],[17],[18],[19]}	$ 88,542,000	^[20],[21]
Investment cost		84,877,000	^{[1],[9],[12],[17],[18],[19]}	88,286,000	^{[4],[20],[21]}
Investments at Fair Value		$ 87,283,000	^{[9],[12],[17],[18],[19]}	90,505,000	^[20],[21]
Communications & Networking \| Senior Secured \| Exit Fee \| Aryaka Networks, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	3.55%				3.55%
Interest Rate and Floor	^[7]	3.55%				3.55%
Communications & Networking \| Senior Secured \| Exit Fee \| Rocket Lab Global Services, LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	3.20%				3.20%
Interest Rate and Floor	^[7]	3.20%				3.20%
Communications & Networking \| Debt Investments
Investment Holdings [Line Items]
Investment cost		$ 98,596,000	^[1]	97,088,000	^[4]
Investments at Fair Value		100,954,000		99,230,000
Consumer & Business Products
Investment Holdings [Line Items]
Investments at Fair Value		25,497,000		28,099,000
Consumer & Business Products \| Equity
Investment Holdings [Line Items]
Investment cost		561,000	^[1]	128,000	^[2]
Investments at Fair Value		185,000		447,000
Consumer & Business Products \| Warrant Investment
Investment Holdings [Line Items]
Investment cost		1,712,000	^[1]	2,145,000	^[2]
Investments at Fair Value		1,122,000		4,354,000
Consumer & Business Products \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Principal Amount	^[4]			23,162,000
Investment cost	^[1]	23,774,000
Investments at Fair Value		24,190,000		23,298,000
Consumer & Business Products \| Grove Collaborative, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[5],[22]	433,000
Investments at Fair Value	^[5],[22]	$ 127,000
Investment, Acquisition Date	^[5]	Apr. 30, 2021
Shares \| shares	^[5],[22]	61,300				61,300
Consumer & Business Products \| Grove Collaborative, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]			433,000
Investments at Fair Value				$ 326,000
Investment, Acquisition Date	^[6]			Apr. 30, 2021
Shares \| shares				83,625				83,625
Consumer & Business Products \| Penumbra Brands, LLC (p.k.a. Gadget Guard) \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2]			$ 228,000
Investments at Fair Value				$ 0
Investment, Acquisition Date	^[6]			Jun. 03, 2014
Shares \| shares				1,662,441				1,662,441
Consumer & Business Products \| TechStyle, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 128,000	^[1]	$ 128,000	^[2]
Investments at Fair Value		$ 58,000		$ 447,000
Investment, Acquisition Date		Apr. 30, 2010	^[5]	Apr. 30, 2010	^[6]
Shares \| shares		42,989		42,989		42,989		42,989
Consumer & Business Products \| TechStyle, Inc. \| Warrant Investment \| Preferred Series B
Investment Holdings [Line Items]
Investment cost	^[1]	$ 1,101,000
Investments at Fair Value		$ 365,000
Investment, Acquisition Date	^[5]	Jul. 16, 2013
Shares \| shares		206,185				206,185
Consumer & Business Products \| Gadget Guard, LLC \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1]	$ 228,000
Investments at Fair Value		$ 0
Investment, Acquisition Date	^[5]	Jun. 03, 2014
Shares \| shares		1,662,441				1,662,441
Consumer & Business Products \| The Neat Company \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 365,000	^[1]	$ 365,000	^[2]
Investments at Fair Value		$ 0		$ 0
Investment, Acquisition Date		Aug. 13, 2014	^[5]	Aug. 13, 2014	^[6]
Shares \| shares		54,054		54,054		54,054		54,054
Consumer & Business Products \| Whoop, Inc. \| Warrant Investment \| Preferred Series C
Investment Holdings [Line Items]
Investment cost		$ 18,000	^[1]	$ 18,000	^[2]
Investments at Fair Value		$ 757,000		$ 1,847,000
Investment, Acquisition Date		Jun. 27, 2018	^[5]	Jun. 27, 2018	^[6]
Shares \| shares		686,270		686,270		686,270		686,270
Consumer & Business Products \| TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) \| Warrant Investment \| Preferred Series B
Investment Holdings [Line Items]
Investment cost	^[2]			$ 1,101,000
Investments at Fair Value				$ 2,181,000
Investment, Acquisition Date	^[6]			Jul. 16, 2013
Shares \| shares				206,185				206,185
Consumer & Business Products \| Senior Secured \| Grove Collaborative, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-04		2025-04		2025-04		2025-04
Investment Interest Rate	^[11]			6.75%				6.75%
Investment, Basis Spread, Variable Rate		5.50%	^[7]	5.50%	^[11]	5.50%	^[7]	5.50%	^[11]
Investment, Interest Rate, Floor		8.75%	^[7]	8.75%	^[11]	8.75%	^[7]	8.75%	^[11]
Interest Rate and Floor	^[11]			6.75%				6.75%
Principal Amount		$ 23,520,000	^[8]	$ 23,520,000	^[23]
Investment cost		23,774,000	^[1],[8]	23,162,000	^[4],[23]
Investments at Fair Value		$ 24,190,000	^[8]	23,298,000	^[23]
Consumer & Business Products \| Senior Secured \| Exit Fee \| Grove Collaborative, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	8.75%				8.75%
Interest Rate and Floor	^[7]	8.75%				8.75%
Consumer & Business Products \| Debt Investments
Investment Holdings [Line Items]
Principal Amount	^[4]			23,162,000
Investment cost	^[1]	$ 23,774,000
Investments at Fair Value		24,190,000		23,298,000
Diversified Financial Services
Investment Holdings [Line Items]
Investments at Fair Value		72,061,000		65,073,000
Diversified Financial Services \| Equity
Investment Holdings [Line Items]
Investment cost		28,444,000	^[1]	28,041,000	^[2]
Investments at Fair Value		38,022,000		32,608,000
Diversified Financial Services \| Debt Investments Under 1 Year Maturity
Investment Holdings [Line Items]
Investment cost	^[4]			403,000
Investments at Fair Value				403,000
Diversified Financial Services \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment cost		36,545,000	^[1]	33,335,000	^[4]
Investments at Fair Value		34,039,000		32,062,000
Diversified Financial Services \| Gibraltar Business Capital, LLC \| Equity
Investment Holdings [Line Items]
Investment cost		28,006,000	^[1]	28,006,000	^[2]
Investments at Fair Value		$ 15,623,000		$ 20,618,000
Shares \| shares		11,432,752		11,432,752		11,432,752		11,432,752
Diversified Financial Services \| Gibraltar Business Capital, LLC \| Equity \| Preferred Series A
Investment Holdings [Line Items]
Investment cost		$ 26,122,000	^[1],[24]	$ 26,122,000	^[2],[25]
Investments at Fair Value		$ 14,489,000	^[24]	$ 19,393,000	^[25]
Investment, Acquisition Date		Mar. 01, 2018	^[5]	Mar. 01, 2018	^[6],[25]
Shares \| shares		10,602,752	^[24]	10,602,752	^[25]	10,602,752	^[24]	10,602,752	^[25]
Diversified Financial Services \| Gibraltar Business Capital, LLC \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,884,000	^[1],[24]	$ 1,884,000	^[2],[25]
Investments at Fair Value		$ 1,134,000	^[24]	$ 1,225,000	^[25]
Investment, Acquisition Date		Mar. 01, 2018	^[5]	Mar. 01, 2018	^[6],[25]
Shares \| shares		830,000	^[24]	830,000	^[25]	830,000	^[24]	830,000	^[25]
Diversified Financial Services \| Gibraltar Business Capital, LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Principal Amount		$ 25,000,000		$ 25,000,000
Investment cost		24,545,000	^[1]	24,485,000	^[4]
Investments at Fair Value		22,039,000		23,212,000
Diversified Financial Services \| Hercules Adviser LLC \| Equity \| Member Units
Investment Holdings [Line Items]
Investment cost		35,000	^[1],[24]	35,000	^[2],[25]
Investments at Fair Value		$ 21,945,000	^[24]	$ 11,990,000	^[25]
Investment, Acquisition Date		Mar. 26, 2021	^[5]	Mar. 26, 2021	^[6],[25]
Shares \| shares		1	^[24]	1	^[25]	1	^[24]	1	^[25]
Diversified Financial Services \| Newfront Insurance Holdings, Inc. \| Equity \| Preferred Series D-2
Investment Holdings [Line Items]
Investment cost	^[1]	$ 403,000
Investments at Fair Value		$ 454,000
Investment, Acquisition Date	^[5]	Sep. 30, 2021
Shares \| shares		210,282				210,282
Diversified Financial Services \| Debt Investments
Investment Holdings [Line Items]
Investment cost		$ 36,545,000	^[1]	$ 33,738,000	^[4]
Investments at Fair Value		$ 34,039,000		$ 32,465,000
Diversified Financial Services \| Unsecured \| Gibraltar Business Capital, LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date				2026-09				2026-09
Principal Amount	^[25]			$ 15,000,000
Diversified Financial Services \| Unsecured \| Hercules Adviser LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-06				2025-06
Investment, Interest Rate, Paid in Cash	^[7]	5.00%				5.00%
Principal Amount	^[24]	$ 12,000,000
Investment cost	^[1],[24]	12,000,000
Investments at Fair Value	^[24]	$ 12,000,000
Diversified Financial Services \| Unsecured 14.50% \| Gibraltar Business Capital, LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-09				2026-09
Investment, Interest Rate, Paid in Cash		14.50%	^[7]	14.50%	^[11],[25]	14.50%	^[7]	14.50%	^[11],[25]
Principal Amount	^[24]	$ 15,000,000
Investment cost		14,701,000	^[1],[24]	$ 14,662,000	^[4],[25]
Investments at Fair Value		$ 13,033,000	^[24]	$ 13,818,000	^[25]
Diversified Financial Services \| Unsecured 11.50% \| Gibraltar Business Capital, LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-09		2026-09		2026-09		2026-09
Investment, Interest Rate, Paid in Cash		11.50%	^[7]	11.50%	^[11],[25]	11.50%	^[7]	11.50%	^[11],[25]
Principal Amount		$ 10,000,000	^[24]	$ 10,000,000	^[25]
Investment cost		9,844,000	^[1],[24]	9,823,000	^[4],[25]
Investments at Fair Value		9,006,000	^[24]	$ 9,394,000	^[25]
Diversified Financial Services \| Unsecured 5.00 % \| Hercules Adviser LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date				2023-05				2023-05
Investment, Interest Rate, Paid in Cash	^[11],[25]			5.00%				5.00%
Principal Amount	^[25]			$ 8,850,000
Investment cost	^[4],[25]			8,850,000
Investments at Fair Value	^[25]			$ 8,850,000
Diversified Financial Services \| Convertible Debt \| Newfront Insurance Holdings, Inc. \| Debt Investments Under 1 Year Maturity
Investment Holdings [Line Items]
Maturity Date				2022-08				2022-08
Investment, Interest Rate, Floor	^[11],[26]			0.19%				0.19%
Investment, Interest Rate, Paid in Kind	^[11],[26]			0.19%				0.19%
Principal Amount	^[26]			$ 403,000
Investment cost	^[4],[26]			403,000
Investments at Fair Value	^[26]			403,000
Investment Funds And Vehicles
Investment Holdings [Line Items]
Investment cost	^[2]			2,032,000
Investments at Fair Value				1,814,000
Investment Funds And Vehicles \| Forbion Growth Opportunities Fund I C V
Investment Holdings [Line Items]
Investment cost	^{[2],[15],[27],[28]}			2,032,000
Investments at Fair Value	^{[15],[27],[28]}			$ 1,814,000
Investment, Acquisition Date	^{[6],[27],[28]}			Nov. 16, 2020
Surgical Devices
Investment Holdings [Line Items]
Investments at Fair Value		1,536,000		$ 1,029,000
Surgical Devices \| Equity
Investment Holdings [Line Items]
Investment cost		1,941,000	^[1]	1,941,000	^[2]
Investments at Fair Value		0		543,000
Surgical Devices \| Warrant Investment
Investment Holdings [Line Items]
Investment cost		152,000	^[1]	206,000	^[2]
Investments at Fair Value		1,536,000		486,000
Surgical Devices \| Gynesonics, Inc. \| Equity
Investment Holdings [Line Items]
Investment cost		1,941,000	^[1]	1,941,000	^[2]
Investments at Fair Value		$ 0		$ 543,000
Shares \| shares		9,595,178		9,595,178		9,595,178		9,595,178
Surgical Devices \| Gynesonics, Inc. \| Equity \| Preferred Series D
Investment Holdings [Line Items]
Investment cost		$ 712,000	^[1]	$ 712,000	^[2]
Investments at Fair Value		$ 0		$ 81,000
Investment, Acquisition Date		Feb. 08, 2013	^[5]	Feb. 08, 2013	^[6]
Shares \| shares		1,991,157		1,991,157		1,991,157		1,991,157
Surgical Devices \| Gynesonics, Inc. \| Equity \| Preferred Series B
Investment Holdings [Line Items]
Investment cost		$ 250,000	^[1]	$ 250,000	^[2]
Investments at Fair Value		$ 0		$ 9,000
Investment, Acquisition Date		Jan. 18, 2007	^[5]	Jan. 18, 2007	^[6]
Shares \| shares		219,298		219,298		219,298		219,298
Surgical Devices \| Gynesonics, Inc. \| Equity \| Preferred Series C
Investment Holdings [Line Items]
Investment cost		$ 282,000	^[1]	$ 282,000	^[2]
Investments at Fair Value		$ 0		$ 26,000
Investment, Acquisition Date		Jun. 16, 2010	^[5]	Jun. 16, 2010	^[6]
Shares \| shares		656,538		656,538		656,538		656,538
Surgical Devices \| Gynesonics, Inc. \| Equity \| Preferred Series E
Investment Holdings [Line Items]
Investment cost		$ 429,000	^[1]	$ 429,000	^[2]
Investments at Fair Value		$ 0		$ 131,000
Investment, Acquisition Date		Jul. 14, 2015	^[5]	Jul. 14, 2015	^[6]
Shares \| shares		2,786,367		2,786,367		2,786,367		2,786,367
Surgical Devices \| Gynesonics, Inc. \| Equity \| Preferred Series F
Investment Holdings [Line Items]
Investment cost		$ 118,000	^[1]	$ 118,000	^[2]
Investments at Fair Value		$ 0		$ 123,000
Investment, Acquisition Date		Dec. 18, 2018	^[5]	Dec. 18, 2018	^[6]
Shares \| shares		1,523,693		1,523,693		1,523,693		1,523,693
Surgical Devices \| Gynesonics, Inc. \| Equity \| Series F One Preferred Stock
Investment Holdings [Line Items]
Investment cost		$ 150,000	^[1]	$ 150,000	^[2]
Investments at Fair Value		$ 0		$ 173,000
Investment, Acquisition Date		Dec. 18, 2018	^[5]	Dec. 18, 2018	^[6]
Shares \| shares		2,418,125		2,418,125		2,418,125		2,418,125
Surgical Devices \| Gynesonics, Inc. \| Warrant Investment \| Preferred Series C
Investment Holdings [Line Items]
Investment cost		$ 13,000	^[1]	$ 67,000	^[2]
Investments at Fair Value		$ 0		$ 6,000
Investment, Acquisition Date		Dec. 05, 2012	^[5]	Feb. 08, 2012	^[6]
Shares \| shares		33,670		151,123		33,670		151,123
Surgical Devices \| TransMedics Group, Inc. (p.k.a Transmedics, Inc.) \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 139,000	^[1],[5]	$ 139,000	^[2],[6]
Investments at Fair Value		$ 1,536,000	^[5]	$ 480,000	^[6]
Investment, Acquisition Date		Nov. 07, 2012	^[5]	Nov. 07, 2012
Shares \| shares		64,440	^[5]	64,440	^[6]	64,440	^[5]	64,440	^[6]
Drug Discovery & Development
Investment Holdings [Line Items]
Investments at Fair Value		$ 1,091,827,000		$ 967,383,000
Drug Discovery & Development \| Equity
Investment Holdings [Line Items]
Investment cost		42,548,000	^[1]	33,401,000	^[2]
Investments at Fair Value		32,844,000		24,860,000
Drug Discovery & Development \| Warrant Investment
Investment Holdings [Line Items]
Investment cost		7,709,000	^[1]	7,393,000	^[2]
Investments at Fair Value		4,074,000		4,745,000
Drug Discovery & Development \| Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment cost	^[1]	2,758,000
Investments at Fair Value		2,665,000
Drug Discovery & Development \| Debt Investments Under 1 Year Maturity
Investment Holdings [Line Items]
Investment cost		16,378,000	^[1]	20,036,000	^[4]
Investments at Fair Value		16,093,000		20,036,000
Drug Discovery & Development \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment cost		1,039,957,000	^[1]	916,421,000	^[2]
Investments at Fair Value		1,036,151,000		915,928,000
Drug Discovery & Development \| Chemocentryx, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		1,000,000	^[1],[5],[29]	1,000,000	^[2],[6],[27]
Investments at Fair Value		$ 891,000	^[5],[29]	$ 628,000	^[6],[27]
Investment, Acquisition Date		Jun. 15, 2020	^[5]	Jun. 15, 2020	^[6],[27]
Shares \| shares		17,241	^[5],[29]	17,241	^[6],[27]	17,241	^[5],[29]	17,241	^[6],[27]
Drug Discovery & Development \| Akero Therapeutics, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1]	$ 1,000,000
Investments at Fair Value	^[5],[29]	$ 1,310,000
Investment, Acquisition Date	^[5]	Sep. 19, 2022
Shares \| shares	^[5],[29]	38,461				38,461
Drug Discovery & Development \| Akero Therapeutics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[5],[29]	$ 56,000
Investments at Fair Value	^[5],[29]	$ 398,000
Investment, Acquisition Date	^[5]	Jun. 15, 2022
Shares \| shares	^[5],[29]	18,360				18,360
Drug Discovery & Development \| Albireo Pharma, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,000,000	^[1],[5],[29]	$ 1,000,000	^[2],[6],[27]
Investments at Fair Value		$ 484,000	^[5],[29]	$ 582,000	^[6],[27]
Investment, Acquisition Date		Sep. 14, 2020	^[5]	Sep. 14, 2020	^[6],[27]
Shares \| shares		25,000	^[5],[29]	25,000	^[6],[27]	25,000	^[5],[29]	25,000	^[6],[27]
Drug Discovery & Development \| Albireo Pharma, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 61,000	^[1],[5],[29]	$ 61,000	^[2],[6],[27]
Investments at Fair Value		$ 26,000	^[5],[29]	$ 42,000	^[6],[27]
Investment, Acquisition Date		Jun. 08, 2020	^[5]	Jun. 08, 2020	^[6],[27]
Shares \| shares		5,311	^[5],[29]	5,311	^[6],[27]	5,311	^[5],[29]	5,311	^[6],[27]
Drug Discovery & Development \| Aveo Pharmaceuticals, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,715,000	^[1],[5]	$ 1,715,000	^[2],[6]
Investments at Fair Value		$ 1,565,000	^[5]	$ 892,000	^[6]
Investment, Acquisition Date		Jul. 31, 2011	^[5]	Jul. 31, 2011	^[6]
Shares \| shares		190,179	^[5]	190,179	^[6]	190,179	^[5]	190,179	^[6]
Drug Discovery & Development \| Axsome Therapeutics, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^{[1],[5],[19],[22],[29]}	$ 4,165,000
Investments at Fair Value	^{[5],[19],[22],[29]}	$ 5,360,000
Investment, Acquisition Date	^[5]	May 09, 2022
Shares \| shares	^{[5],[19],[22],[29]}	127,021				127,021
Drug Discovery & Development \| Axsome Therapeutics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 880,000	^{[1],[5],[19],[29]}	$ 681,000	^[2],[6],[27]
Investments at Fair Value		$ 783,000	^{[5],[19],[29]}	$ 142,000	^[6],[27]
Investment, Acquisition Date		Sep. 25, 2020	^[5]	Sep. 25, 2020	^[6],[27]
Shares \| shares		40,396	^{[5],[19],[22],[29]}	15,541	^[6],[27]	40,396	^{[5],[19],[22],[29]}	15,541	^[6],[27]
Drug Discovery & Development \| Bicycle Therapeutics PLC \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,871,000	^{[1],[5],[29],[30]}	$ 1,871,000	^{[2],[6],[27],[28]}
Investments at Fair Value		$ 2,282,000	^{[5],[29],[30]}	$ 5,971,000	^{[6],[27],[28]}
Investment, Acquisition Date		Oct. 05, 2020	^[5]	Oct. 05, 2020	^{[6],[27],[28]}
Shares \| shares		98,100	^{[5],[29],[30]}	98,100	^{[6],[27],[28]}	98,100	^{[5],[29],[30]}	98,100	^{[6],[27],[28]}
Drug Discovery & Development \| BridgeBio Pharma, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 2,255,000	^[1],[5]	$ 2,255,000	^[2],[6]
Investments at Fair Value		$ 2,299,000	^[5]	$ 3,859,000	^[6]
Investment, Acquisition Date		Jun. 21, 2018	^[5]	Jun. 21, 2018	^[6]
Shares \| shares		231,329	^[5]	231,329	^[6]	231,329	^[5]	231,329	^[6]
Drug Discovery & Development \| Cellarity, Inc. \| Warrant Investment \| Preferred Series B
Investment Holdings [Line Items]
Investment cost		$ 287,000	^[1],[31]	$ 287,000	^[2],[32]
Investments at Fair Value		$ 370,000	^[31]	$ 287,000	^[32]
Investment, Acquisition Date		Dec. 08, 2021	^[5]	Dec. 08, 2021	^[6]
Shares \| shares		100,000	^[31]	100,000	^[32]	100,000	^[31]	100,000	^[32]
Drug Discovery & Development \| Century Therapeutics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 37,000	^[1],[5]	$ 37,000	^[2],[6]
Investments at Fair Value		$ 16,000	^[5]	$ 64,000	^[6]
Investment, Acquisition Date		Sep. 14, 2020	^[5]	Sep. 14, 2020	^[6]
Shares \| shares		16,112	^[5]	16,112	^[6]	16,112	^[5]	16,112	^[6]
Drug Discovery & Development \| enGene, Inc. \| Warrant Investment \| Preferred Series 3
Investment Holdings [Line Items]
Investment cost	^{[1],[29],[30]}	$ 72,000
Investments at Fair Value	^[29],[30]	$ 31,000
Investment, Acquisition Date	^[5]	Dec. 30, 2021
Shares \| shares	^[29],[30]	133,692				133,692
Drug Discovery & Development \| enGene, Inc. \| Warrant Investment \| Preferred Series 3 Class C
Investment Holdings [Line Items]
Investment cost	^{[2],[27],[28]}			$ 64,000
Investments at Fair Value	^[27],[28]			$ 64,000
Investment, Acquisition Date	^{[6],[27],[28]}			Dec. 30, 2021
Shares \| shares	^[27],[28]			84,714				84,714
Drug Discovery & Development \| Hibercell, Inc. \| Equity \| Preferred Series B
Investment Holdings [Line Items]
Investment cost		$ 4,250,000	^[1],[31]	$ 4,250,000	^[2],[32]
Investments at Fair Value		$ 2,917,000	^[31]	$ 3,264,000	^[32]
Investment, Acquisition Date		May 07, 2021	^[5]	May 07, 2021	^[6]
Shares \| shares		3,466,840	^[31]	3,466,840	^[32]	3,466,840	^[31]	3,466,840	^[32]
Drug Discovery & Development \| HilleVax, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[5]	$ 4,000,000
Investments at Fair Value	^[5]	$ 4,021,000
Investment, Acquisition Date	^[5]	May 03, 2022
Shares \| shares	^[5]	235,295				235,295
Drug Discovery & Development \| Humanigen, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 800,000	^[1],[5],[29]	$ 800,000	^[2],[6],[27]
Investments at Fair Value		$ 8,000	^[5],[29]	$ 161,000	^[6],[27]
Investment, Acquisition Date		Mar. 31, 2021	^[5]	Mar. 31, 2021	^[6],[27]
Shares \| shares		43,243	^[5],[29]	43,243	^[6],[27]	43,243	^[5],[29]	43,243	^[6],[27]
Drug Discovery & Development \| Kaleido Biosciences, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[6]			$ 1,000,000
Investments at Fair Value	^[6]			$ 207,000
Investment, Acquisition Date	^[6]			Feb. 10, 2021
Shares \| shares	^[6]			86,585				86,585
Drug Discovery & Development \| Madrigal Pharmaceutical, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[5],[29]	$ 177,000
Investments at Fair Value	^[5],[29]	$ 214,000
Investment, Acquisition Date	^[5]	May 09, 2022
Shares \| shares	^[5],[29]	10,131				10,131
Drug Discovery & Development \| Phathom Pharmaceuticals, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 848,000	^{[1],[5],[19],[29],[31]}	$ 848,000	^{[2],[6],[27],[32]}
Investments at Fair Value		$ 113,000	^{[5],[19],[29],[31]}	$ 307,000	^{[6],[21],[27],[32]}
Investment, Acquisition Date		Sep. 17, 2021	^[5]	Sep. 17, 2021	^[6],[27]
Shares \| shares		64,687	^{[5],[19],[29],[31]}	64,687	^{[6],[21],[27],[32]}	64,687	^{[5],[19],[29],[31]}	64,687	^{[6],[21],[27],[32]}
Drug Discovery & Development \| Provention Bio, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[5]	$ 281,000
Investments at Fair Value	^[5]	$ 224,000
Investment, Acquisition Date	^[5]	Sep. 15, 2022
Shares \| shares	^[5]	111,934				111,934
Drug Discovery & Development \| Redshift Bioanalytics, Inc. \| Warrant Investment
Investment Holdings [Line Items]
Investments at Fair Value	^[31]	$ 18,000
Drug Discovery & Development \| Redshift Bioanalytics, Inc. \| Warrant Investment \| Preferred Series E
Investment Holdings [Line Items]
Investment cost	^[1],[31]	$ 20,000
Investment, Acquisition Date	^[5]	Mar. 23, 2022
Shares \| shares	^[31]	475,510				475,510
Drug Discovery & Development \| Scynexis, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 296,000	^[1],[5]	$ 188,000	^[2],[6]
Investments at Fair Value		$ 47,000	^[5]	$ 142,000	^[6]
Investment, Acquisition Date		May 14, 2021	^[5]	May 14, 2021	^[6]
Shares \| shares		106,035	^[5]	90,887	^[6]	106,035	^[5]	90,887	^[6]
Drug Discovery & Development \| Tarsus Pharmaceuticals, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[5],[29]	$ 2,100,000
Investments at Fair Value	^[5],[29]	$ 2,663,000
Investment, Acquisition Date	^[5]	May 05, 2022
Shares \| shares	^[5],[29]	155,555				155,555
Drug Discovery & Development \| TG Therapeutics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,033,000	^{[1],[5],[18],[29]}	$ 1,033,000	^{[2],[6],[27],[33]}
Investments at Fair Value		$ 335,000	^{[5],[18],[29]}	$ 2,172,000	^{[6],[27],[33]}
Investment, Acquisition Date		Feb. 28, 2019	^[5]	Feb. 28, 2019	^[6],[27]
Shares \| shares		231,613	^{[5],[18],[29]}	231,613	^{[6],[27],[33]}	231,613	^{[5],[18],[29]}	231,613	^{[6],[27],[33]}
Drug Discovery & Development \| Uni Qure B V \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 332,000	^{[1],[5],[19],[29],[30]}	$ 332,000	^{[2],[6],[21],[27],[28]}
Investments at Fair Value		$ 322,000	^{[5],[19],[29],[30]}	$ 356,000	^{[6],[21],[27],[28]}
Investment, Acquisition Date		Jan. 31, 2019	^[5]	Jan. 31, 2019	^{[6],[27],[28]}
Shares \| shares		17,175	^{[5],[19],[29],[30]}	17,175	^{[6],[21],[27],[28]}	17,175	^{[5],[19],[29],[30]}	17,175	^{[6],[21],[27],[28]}
Drug Discovery & Development \| Valo Health L L C \| Equity \| Preferred Series B
Investment Holdings [Line Items]
Investment cost		$ 3,000,000	^[1]	$ 3,000,000	^[2]
Investments at Fair Value		$ 3,622,000		$ 4,650,000
Investment, Acquisition Date		Dec. 11, 2020	^[5]	Dec. 11, 2020	^[6]
Shares \| shares		510,308		510,308		510,308		510,308
Drug Discovery & Development \| Valo Health L L C \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investments at Fair Value		$ 242,000
Investment, Acquisition Date	^[5]	Jun. 15, 2020
Drug Discovery & Development \| Valo Health L L C \| Warrant Investment \| Common Units
Investment Holdings [Line Items]
Investment cost	^[1]	$ 256,000
Shares \| shares		102,216				102,216
Drug Discovery & Development \| X Four Pharmaceuticals Inc \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 2,522,000	^[1],[5]	$ 1,641,000	^[2],[6]
Investments at Fair Value		$ 1,901,000	^[5]	$ 454,000	^[6]
Investment, Acquisition Date		Nov. 26, 2019	^[5]	Nov. 26, 2019	^[6]
Shares \| shares		1,111,519	^[5]	198,277	^[6]	1,111,519	^[5]	198,277	^[6]
Drug Discovery & Development \| X Four Pharmaceuticals Inc \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 792,000	^[1],[5]	$ 673,000	^[2],[6]
Investments at Fair Value		$ 628,000	^[5]	$ 2,000	^[6]
Investment, Acquisition Date		Mar. 18, 2019	^[5]	Mar. 18, 2019	^[6]
Shares \| shares		1,021,576	^[5]	108,334	^[6]	1,021,576	^[5]	108,334	^[6]
Drug Discovery & Development \| Applied Molecular Transport \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 42,000	^[1],[5],[29]	$ 42,000	^[2],[6],[27]
Investments at Fair Value		$ 1,000	^[5],[29]	$ 14,000	^[6],[27]
Investment, Acquisition Date		Apr. 06, 2021	^[5]	Apr. 06, 2021	^[6],[27]
Shares \| shares		1,000	^[5],[29]	1,000	^[6],[27]	1,000	^[5],[29]	1,000	^[6],[27]
Drug Discovery & Development \| Avalo Therapeutics, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,000,000	^[1],[5]	$ 1,000,000	^[2],[6]
Investments at Fair Value		$ 33,000	^[5]	$ 202,000	^[6]
Investment, Acquisition Date		Aug. 19, 2014	^[5]	Aug. 19, 2014	^[6]
Shares \| shares		9,924	^[5]	119,087	^[6]	9,924	^[5]	119,087	^[6]
Drug Discovery & Development \| Concert Pharmaceuticals, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,367,000	^[1],[5],[29]	$ 1,367,000	^[2],[6],[27]
Investments at Fair Value		$ 474,000	^[5],[29]	$ 223,000	^[6],[27]
Investment, Acquisition Date		Feb. 13, 2019	^[5]	Feb. 13, 2019	^[6],[27]
Shares \| shares		70,796	^[5],[29]	70,796	^[6],[27]	70,796	^[5],[29]	70,796	^[6],[27]
Drug Discovery & Development \| Concert Pharmaceuticals, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[6],[27]			$ 178,000
Investments at Fair Value	^[6],[27]			$ 3,000
Investment, Acquisition Date	^[6],[27]			Jun. 08, 2017
Shares \| shares	^[6],[27]			61,273				61,273
Drug Discovery & Development \| Dare Biosciences, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,000,000	^[1],[5]	$ 1,000,000	^[2],[6]
Investments at Fair Value		$ 14,000	^[5]	$ 27,000	^[6]
Investment, Acquisition Date		Jan. 08, 2015	^[5]	Jan. 08, 2015	^[6]
Shares \| shares		13,550	^[5]	13,550	^[6]	13,550	^[5]	13,550	^[6]
Drug Discovery & Development \| Dynavax Technologies \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 550,000	^[1],[5],[29]	$ 550,000	^[2],[6],[27]
Investments at Fair Value		$ 209,000	^[5],[29]	$ 281,000	^[6],[27]
Investment, Acquisition Date		Jul. 22, 2015	^[5]	Jul. 22, 2015	^[6],[27]
Shares \| shares		20,000	^[5],[29]	20,000	^[6],[27]	20,000	^[5],[29]	20,000	^[6],[27]
Drug Discovery & Development \| NorthSea Therapeutics \| Equity \| Preferred Series C
Investment Holdings [Line Items]
Investment cost		$ 2,000,000	^{[1],[29],[30]}	$ 2,000,000	^{[2],[27],[28]}
Investments at Fair Value		$ 1,515,000	^[29],[30]	$ 2,000,000	^[27],[28]
Investment, Acquisition Date		Dec. 15, 2021	^[5]	Dec. 15, 2021	^{[6],[27],[28]}
Shares \| shares		983	^[29],[30]	983	^[27],[28]	983	^[29],[30]	983	^[27],[28]
Drug Discovery & Development \| Paratek Pharmaceuticals, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 2,744,000	^[1],[5]	$ 2,744,000	^[2],[6]
Investments at Fair Value		$ 196,000	^[5]	$ 343,000	^[6]
Investment, Acquisition Date		Feb. 26, 2007	^[5]	Feb. 26, 2007	^[6]
Shares \| shares		76,362	^[5]	76,362	^[6]	76,362	^[5]	76,362	^[6]
Drug Discovery & Development \| Paratek Pharmaceuticals, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 520,000	^[1],[5]	$ 546,000	^[2],[6]
Investments at Fair Value		$ 72,000	^[5]	$ 427,000	^[6]
Investment, Acquisition Date		Aug. 01, 2018	^[5]	Jun. 27, 2017	^[6]
Shares \| shares		426,866	^[5]	432,240	^[6]	426,866	^[5]	432,240	^[6]
Drug Discovery & Development \| Rocket Pharmaceuticals, Ltd. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,500,000	^[1],[5]	$ 1,500,000	^[2],[6]
Investments at Fair Value		$ 15,000	^[5]	$ 21,000	^[6]
Investment, Acquisition Date		Aug. 22, 2007	^[5]	Aug. 22, 2007	^[6]
Shares \| shares		944	^[5]	944	^[6]	944	^[5]	944	^[6]
Drug Discovery & Development \| Savara, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 203,000	^[1],[5]	$ 202,000	^[2],[6]
Investments at Fair Value		$ 17,000	^[5]	$ 14,000	^[6]
Investment, Acquisition Date		Aug. 11, 2015	^[5]	Aug. 11, 2015	^[6]
Shares \| shares		11,119	^[5]	11,119	^[6]	11,119	^[5]	11,119	^[6]
Drug Discovery & Development \| Sio Gene Therapies, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 1,269,000	^[1],[5]	$ 1,269,000	^[2],[6],[27]
Investments at Fair Value		$ 4,000	^[5]	$ 21,000	^[6],[27]
Investment, Acquisition Date		Feb. 02, 2017	^[5]	Feb. 02, 2017	^[6],[27]
Shares \| shares		16,228	^[5]	16,228	^[6],[27]	16,228	^[5]	16,228	^[6],[27]
Drug Discovery & Development \| Tricida, Inc. \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 863,000	^[1],[5]	$ 863,000	^[2],[6]
Investments at Fair Value		$ 721,000	^[5]	$ 658,000	^[6]
Investment, Acquisition Date		Feb. 28, 2018	^[5]	Feb. 28, 2018	^[6]
Shares \| shares		68,816	^[5]	68,816	^[6]	68,816	^[5]	68,816	^[6]
Drug Discovery & Development \| Tricida, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 280,000	^[1],[5]	$ 280,000	^[2],[6]
Investments at Fair Value		$ 22,000	^[5]	$ 20,000	^[6]
Investment, Acquisition Date		Mar. 27, 2019	^[5]	Mar. 27, 2019	^[6]
Shares \| shares		31,352	^[5]	31,352	^[6]	31,352	^[5]	31,352	^[6]
Drug Discovery & Development \| ADMA Biologics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 295,000	^[1],[5]	$ 295,000	^[2],[6]
Investments at Fair Value		$ 2,000	^[5]	$ 1,000	^[6]
Investment, Acquisition Date		Dec. 21, 2012	^[5]	Dec. 21, 2012	^[6]
Shares \| shares		89,750	^[5]	89,750	^[6]	89,750	^[5]	89,750	^[6]
Drug Discovery & Development \| Brickell Biotech, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[6]			$ 119,000
Investments at Fair Value	^[6]			$ 0
Investment, Acquisition Date	^[6]			Feb. 18, 2016
Shares \| shares	^[6]			9,005				9,005
Drug Discovery & Development \| Dermavant Sciences Ltd. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 101,000	^{[1],[18],[29],[30]}	$ 101,000	^{[2],[27],[33]}
Investments at Fair Value		$ 104,000	^{[18],[29],[30]}	$ 354,000	^[27],[33]
Investment, Acquisition Date		May 31, 2019	^[5]	May 31, 2019	^[6],[27]
Shares \| shares		223,642	^{[18],[29],[30]}	223,642	^[27],[33]	223,642	^{[18],[29],[30]}	223,642	^[27],[33]
Drug Discovery & Development \| Evofem Biosciences, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 266,000	^[1],[5]	$ 266,000	^[2],[6]
Investments at Fair Value		$ 0	^[5]	$ 0	^[6]
Investment, Acquisition Date		Jun. 11, 2014	^[5]	Jun. 11, 2014	^[6]
Shares \| shares		520	^[5]	7,806	^[6]	520	^[5]	7,806	^[6]
Drug Discovery & Development \| Myovant Sciences, Ltd. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 460,000	^{[1],[5],[29],[30]}	$ 460,000	^[2],[6],[27]
Investments at Fair Value		$ 429,000	^{[5],[29],[30]}	$ 267,000	^[6],[27]
Investment, Acquisition Date		Oct. 16, 2017	^[5]	Oct. 16, 2017	^[6],[27]
Shares \| shares		73,710	^{[5],[29],[30]}	73,710	^[6],[27]	73,710	^{[5],[29],[30]}	73,710	^[6],[27]
Drug Discovery & Development \| Stealth Bio Therapeutics Corp. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 158,000	^{[1],[5],[29],[30]}	$ 158,000	^[2],[6],[27]
Investments at Fair Value		$ 0	^{[5],[29],[30]}	$ 0	^[6],[27]
Investment, Acquisition Date		Jun. 30, 2017	^[5]	Jun. 30, 2017	^[6],[27]
Shares \| shares		500,000	^{[5],[29],[30]}	500,000	^[6],[27]	500,000	^{[5],[29],[30]}	500,000	^[6],[27]
Drug Discovery & Development \| Yumanity Therapeutics, Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 110,000	^[1],[5]	$ 110,000	^[2],[6]
Investments at Fair Value		$ 0	^[5]	$ 3,000	^[6]
Investment, Acquisition Date		Dec. 20, 2019	^[5]	Dec. 20, 2019	^[6]
Shares \| shares		15,414	^[5]	15,414	^[6]	15,414	^[5]	15,414	^[6]
Drug Discovery & Development \| Fresh Tracks Therapeutics, Inc. (p.k.a. Brickell Biotech, Inc.) \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[1],[5]	$ 119,000
Investments at Fair Value	^[5]	$ 0
Investment, Acquisition Date	^[5]	Feb. 18, 2016
Shares \| shares	^[5]	200				200
Drug Discovery & Development \| Forbion Growth Opportunities Fund I C V \| Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment cost	^{[1],[10],[29],[30]}	$ 2,353,000
Investments at Fair Value	^{[10],[29],[30]}	$ 2,291,000
Investment, Acquisition Date	^[5]	Nov. 16, 2020
Drug Discovery & Development \| Forbion Growth Opportunities Fund I I C V \| Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment cost	^{[1],[10],[29],[30]}	$ 405,000
Investments at Fair Value	^{[10],[29],[30]}	$ 374,000
Investment, Acquisition Date	^[5]	Jun. 23, 2022
Drug Discovery & Development \| Valo Health, LLC (p.k.a. Integral Health Holdings, LLC) \| Warrant Investment \| Common Units
Investment Holdings [Line Items]
Investment cost	^[2]			$ 256,000
Investments at Fair Value				$ 441,000
Investment, Acquisition Date	^[6]			Jun. 15, 2020
Shares \| shares				102,216				102,216
Drug Discovery & Development \| Acacia Pharma Inc. \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost		$ 304,000	^{[1],[29],[30]}	$ 305,000	^{[2],[6],[27],[28]}
Investments at Fair Value		$ 0	^[29],[30]	$ 6,000	^{[6],[27],[28]}
Investment, Acquisition Date		Jun. 29, 2018	^[5]	Jun. 29, 2018	^{[6],[27],[28]}
Shares \| shares		201,330	^[29],[30]	201,330	^{[6],[27],[28]}	201,330	^[29],[30]	201,330	^{[6],[27],[28]}
Drug Discovery & Development \| Genocea Biosciences Inc \| Equity \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[6]			$ 2,000,000
Investments at Fair Value	^[6]			$ 32,000
Investment, Acquisition Date	^[6]			Nov. 20, 2014
Shares \| shares	^[6]			27,933				27,933
Drug Discovery & Development \| Genocea Biosciences Inc \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[6]			$ 165,000
Investments at Fair Value	^[6]			$ 1,000
Investment, Acquisition Date	^[6]			Apr. 24, 2018
Shares \| shares	^[6]			41,176				41,176
Drug Discovery & Development \| Motif Bio P L C \| Warrant Investment \| Common Stock
Investment Holdings [Line Items]
Investment cost	^[2],[27]			$ 282,000
Investments at Fair Value	^[27]			$ 0
Investment, Acquisition Date	^[6],[27]			Jan. 27, 2020
Shares \| shares	^[27]			121,337,041				121,337,041
Drug Discovery & Development \| Senior Secured \| Chemocentryx, Inc. \| Debt Investments Under 1 Year Maturity
Investment Holdings [Line Items]
Maturity Date		2022-12		2022-12		2022-12		2022-12
Investment Interest Rate	^[11],[27]			6.25%				6.25%
Investment, Basis Spread, Variable Rate		3.30%	^[7]	3.30%	^[11],[27]	3.30%	^[7]	3.30%	^[11],[27]
Investment, Interest Rate, Floor		8.05%	^[7]	8.05%	^[11],[27]	8.05%	^[7]	8.05%	^[11],[27]
Interest Rate and Floor	^[11],[27]			6.25%				6.25%
Principal Amount		$ 11,451,000	^[17],[29]	$ 18,951,000	^[27]
Investment cost		12,677,000	^{[1],[17],[29]}	20,036,000	^[4],[27]
Investments at Fair Value		$ 12,780,000	^[17],[29]	$ 20,036,000	^[27]
Drug Discovery & Development \| Senior Secured \| Chemocentryx, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-02		2025-02		2025-02		2025-02
Investment Interest Rate	^[11],[27]			7.15%				7.15%
Investment, Basis Spread, Variable Rate		3.25%	^[7]	3.25%	^[11],[27]	3.25%	^[7]	3.25%	^[11],[27]
Investment, Interest Rate, Floor		8.50%	^[7]	8.50%	^[11],[27]	8.50%	^[7]	8.50%	^[11],[27]
Interest Rate and Floor	^[11],[27]			7.15%				7.15%
Principal Amount		$ 5,000,000	^[17],[29]	$ 5,000,000	^[27]
Investment cost		5,214,000	^{[1],[17],[29]}	5,161,000	^[2],[27]
Investments at Fair Value		$ 5,408,000	^[17],[29]	$ 5,070,000	^[27]
Drug Discovery & Development \| Senior Secured \| Nabriva Therapeutics \| Debt Investments Under 1 Year Maturity
Investment Holdings [Line Items]
Maturity Date		2023-06				2023-06
Investment, Basis Spread, Variable Rate	^[7]	4.30%				4.30%
Investment, Interest Rate, Floor	^[7]	9.80%				9.80%
Principal Amount	^{[17],[29],[30]}	$ 3,077,000
Investment cost	^{[1],[17],[29],[30]}	3,701,000
Investments at Fair Value	^{[17],[29],[30]}	$ 3,313,000
Drug Discovery & Development \| Senior Secured \| Nabriva Therapeutics \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date				2023-06				2023-06
Investment Interest Rate	^{[11],[27],[28]}			6.95%				6.95%
Investment, Basis Spread, Variable Rate	^{[11],[27],[28]}			4.30%				4.30%
Investment, Interest Rate, Floor	^{[11],[27],[28]}			9.80%				9.80%
Interest Rate and Floor	^{[11],[27],[28]}			6.95%				6.95%
Principal Amount	^[27],[28]			$ 5,000,000
Investment cost	^{[2],[27],[28]}			5,500,000
Investments at Fair Value	^[27],[28]			$ 5,459,000
Drug Discovery & Development \| Senior Secured \| Akero Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2027-01				2027-01
Investment, Basis Spread, Variable Rate	^[7]	3.65%				3.65%
Investment, Interest Rate, Floor	^[7]	7.65%				7.65%
Principal Amount	^[10],[29]	$ 5,000,000
Investment cost	^{[1],[10],[29]}	4,966,000
Investments at Fair Value	^[10],[29]	$ 4,983,000
Drug Discovery & Development \| Senior Secured \| Albireo Pharma, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date				2024-07				2024-07
Investment Interest Rate	^[11],[27]			6.95%				6.95%
Investment, Basis Spread, Variable Rate	^[11],[27]			5.90%				5.90%
Investment, Interest Rate, Floor	^[11],[27]			9.15%				9.15%
Interest Rate and Floor	^[11],[27]			6.95%				6.95%
Principal Amount	^[14],[27]			$ 10,000,000
Investment cost	^{[4],[14],[27]}			10,229,000
Investments at Fair Value	^[14],[27]			$ 10,268,000
Drug Discovery & Development \| Senior Secured \| Alladapt Immunotherapeutics Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-09				2026-09
Investment, Basis Spread, Variable Rate	^[7]	3.65%				3.65%
Investment, Interest Rate, Floor	^[7]	8.40%				8.40%
Principal Amount	^[10]	$ 15,000,000
Investment cost	^[1],[10]	14,858,000
Investments at Fair Value	^[10]	$ 14,858,000
Drug Discovery & Development \| Senior Secured \| Aldeyra Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2023-10		2023-10		2023-10		2023-10
Investment Interest Rate	^[11]			6.95%				6.95%
Investment, Basis Spread, Variable Rate		3.10%	^[7]	3.10%	^[11]	3.10%	^[7]	3.10%	^[11]
Investment, Interest Rate, Floor		8.60%	^[7]	8.60%	^[11]	8.60%	^[7]	8.60%	^[11]
Interest Rate and Floor	^[11]			6.95%				6.95%
Principal Amount		$ 15,000,000	^[12]	$ 15,000,000
Investment cost		15,817,000	^[1],[12]	15,639,000	^[4]
Investments at Fair Value		$ 15,608,000	^[12]	$ 15,653,000
Drug Discovery & Development \| Senior Secured \| Applied Genetic Technologies Corporation \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2024-04		2024-04		2024-04		2024-04
Investment Interest Rate	^[11]			9.75%				9.75%
Investment, Basis Spread, Variable Rate		6.50%	^[7]	6.50%	^[11]	6.50%	^[7]	6.50%	^[11]
Investment, Interest Rate, Floor	^[7]	9.75%				9.75%
Interest Rate and Floor	^[11]			9.75%				9.75%
Principal Amount		$ 15,609,000	^[17]	$ 20,000,000
Investment cost		16,450,000	^[1],[17]	20,416,000	^[4]
Investments at Fair Value		$ 16,308,000	^[17]	$ 20,339,000
Drug Discovery & Development \| Senior Secured \| ATAI Life Sciences N.V. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-08				2026-08
Investment, Basis Spread, Variable Rate	^[7]	4.55%				4.55%
Investment, Interest Rate, Floor	^[7]	8.55%				8.55%
Principal Amount	^{[10],[29],[30]}	$ 10,500,000
Investment cost	^{[1],[10],[29],[30]}	10,467,000
Investments at Fair Value	^{[10],[29],[30]}	$ 10,467,000
Drug Discovery & Development \| Senior Secured \| Aveo Pharmaceuticals, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2024-09		2024-09		2024-09		2024-09
Investment, Basis Spread, Variable Rate		6.40%	^[7]	6.40%	^[11]	6.40%	^[7]	6.40%	^[11]
Investment, Interest Rate, Floor		9.65%	^[7]	9.65%	^[11]	9.65%	^[7]	9.65%	^[11]
Principal Amount		$ 40,000,000	^[12],[31]	$ 40,000,000	^[14],[32]
Investment cost		41,439,000	^{[1],[12],[31]}	40,842,000	^{[4],[14],[32]}
Investments at Fair Value		$ 41,374,000	^[12],[31]	$ 40,776,000	^[14],[32]
Drug Discovery & Development \| Senior Secured \| Axsome Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-10		2026-10		2026-10		2026-10
Investment Interest Rate	^[11],[27]			5.82%				5.82%
Investment, Basis Spread, Variable Rate		5.70%	^[7]	5.70%	^[11],[27]	5.70%	^[7]	5.70%	^[11],[27]
Investment, Interest Rate, Floor		8.95%	^[7]	8.95%	^[11],[27]	8.95%	^[7]	8.95%	^[11],[27]
Interest Rate and Floor	^[11],[27]			5.82%				5.82%
Principal Amount		$ 81,725,000	^{[10],[12],[18],[19],[29]}	$ 50,000,000	^[27],[33]
Investment cost		81,388,000	^{[1],[10],[12],[18],[19],[29]}	49,542,000	^{[4],[27],[33]}
Investments at Fair Value		$ 79,295,000	^{[10],[12],[18],[19],[29]}	$ 48,859,000	^[27],[33]
Drug Discovery & Development \| Senior Secured \| Bicycle Therapeutics PLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-07		2024-10		2025-07		2024-10
Investment Interest Rate	^{[11],[27],[28]}			5.00%				5.00%
Investment, Basis Spread, Variable Rate		4.55%	^[7]	5.60%	^{[11],[27],[28]}	4.55%	^[7]	5.60%	^{[11],[27],[28]}
Investment, Interest Rate, Floor		8.05%	^[7]	8.85%	^{[11],[27],[28]}	8.05%	^[7]	8.85%	^{[11],[27],[28]}
Interest Rate and Floor	^{[11],[27],[28]}			5.00%				5.00%
Principal Amount		$ 11,500,000	^{[12],[18],[29],[30]}	$ 24,000,000	^{[14],[15],[27],[28],[33]}
Investment cost		11,724,000	^{[1],[12],[18],[29],[30]}	24,271,000	^{[4],[14],[15],[27],[28],[33]}
Investments at Fair Value		$ 11,619,000	^{[12],[18],[29],[30]}	$ 24,454,000	^{[14],[15],[27],[28],[33]}
Drug Discovery & Development \| Senior Secured \| BiomX, INC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-09		2025-09		2025-09		2025-09
Investment, Basis Spread, Variable Rate		5.70%	^[7]	5.70%	^{[11],[27],[28]}	5.70%	^[7]	5.70%	^{[11],[27],[28]}
Investment, Interest Rate, Floor		8.95%	^[7]	8.95%	^{[11],[27],[28]}	8.95%	^[7]	8.95%	^{[11],[27],[28]}
Principal Amount		$ 9,000,000	^{[12],[29],[30]}	$ 9,000,000	^{[14],[27],[28]}
Investment cost		9,125,000	^{[1],[12],[29],[30]}	8,980,000	^{[4],[14],[27],[28]}
Investments at Fair Value		$ 9,004,000	^{[12],[29],[30]}	$ 8,980,000	^{[14],[27],[28]}
Drug Discovery & Development \| Senior Secured \| BridgeBio Pharma, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-11		2026-11		2026-11		2026-11
Investment, Interest Rate, Paid in Cash		9.00%	^[7]	9.00%	^[11]	9.00%	^[7]	9.00%	^[11]
Investment Interest Rate	^[11]			2.00%				2.00%
Interest Rate and Floor	^[11]			2.00%				2.00%
Principal Amount		$ 37,022,000	^{[9],[17],[18]}	$ 38,000,000
Investment cost		36,694,000	^{[1],[9],[17],[18]}	37,462,000	^[4]
Investments at Fair Value		$ 33,561,000	^{[9],[17],[18]}	$ 37,462,000
Drug Discovery & Development \| Senior Secured \| Cellarity, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-06		2026-06		2026-06		2026-06
Investment Interest Rate	^[11]			3.75%				3.75%
Investment, Basis Spread, Variable Rate		5.70%	^[7]	5.70%	^[11]	5.70%	^[7]	5.70%	^[11]
Investment, Interest Rate, Floor		8.95%	^[7]	8.95%	^[11]	8.95%	^[7]	8.95%	^[11]
Interest Rate and Floor	^[11]			3.75%				3.75%
Principal Amount		$ 30,000,000	^[17],[31]	$ 30,000,000	^[32]
Investment cost		29,734,000	^{[1],[17],[31]}	29,422,000	^[4],[32]
Investments at Fair Value		$ 29,943,000	^[17],[31]	$ 29,422,000	^[32]
Drug Discovery & Development \| Senior Secured \| Century Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2024-04		2024-04		2024-04		2024-04
Investment Interest Rate	^[11]			3.95%				3.95%
Investment, Basis Spread, Variable Rate		6.30%	^[7]	6.30%	^[11]	6.30%	^[7]	6.30%	^[11]
Investment, Interest Rate, Floor		9.55%	^[7]	9.55%	^[11]	9.55%	^[7]	9.55%	^[11]
Interest Rate and Floor	^[11]			3.95%				3.95%
Principal Amount		$ 10,000,000	^[12]	$ 10,000,000	^[14]
Investment cost		10,197,000	^[1],[12]	10,075,000	^[4],[14]
Investments at Fair Value		$ 10,261,000	^[12]	$ 10,361,000	^[14]
Drug Discovery & Development \| Senior Secured \| Codiak Biosciences, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-10		2025-10		2025-10		2025-10
Investment Interest Rate	^[11]			5.50%				5.50%
Investment, Basis Spread, Variable Rate		5.00%	^[7]	5.00%	^[11]	5.00%	^[7]	5.00%	^[11]
Investment, Interest Rate, Floor		8.25%	^[7]	8.25%	^[11]	8.25%	^[7]	8.25%	^[11]
Interest Rate and Floor	^[11]			5.50%				5.50%
Principal Amount		$ 25,000,000	^[12]	$ 25,000,000	^[14]
Investment cost		25,681,000	^[1],[12]	25,459,000	^[2],[14]
Investments at Fair Value		$ 25,076,000	^[12]	$ 25,316,000	^[14]
Drug Discovery & Development \| Senior Secured \| Corium, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-09		2026-09		2026-09		2026-09
Investment Interest Rate	^[11]			7.75%				7.75%
Investment, Basis Spread, Variable Rate		5.70%	^[7]	5.70%	^[11]	5.70%	^[7]	5.70%	^[11]
Investment, Interest Rate, Floor		8.95%	^[7]	8.95%	^[11]	8.95%	^[7]	8.95%	^[11]
Interest Rate and Floor	^[11]			7.75%				7.75%
Principal Amount		$ 132,675,000	^[17],[19]	$ 91,500,000	^[21]
Investment cost		133,069,000	^{[1],[17],[19]}	90,997,000	^[2],[21]
Investments at Fair Value		$ 135,828,000	^[17],[19]	$ 90,997,000	^[21]
Drug Discovery & Development \| Senior Secured \| Eloxx Pharmaceuticals, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-04		2025-04		2025-04		2025-04
Investment Interest Rate	^[11]			6.25%				6.25%
Investment, Basis Spread, Variable Rate	^[7]	6.25%				6.25%
Investment, Interest Rate, Floor		9.50%	^[7]	9.50%	^[11]	9.50%	^[7]	9.50%	^[11]
Interest Rate and Floor	^[11]			6.25%				6.25%
Principal Amount		$ 12,500,000	^[31]	$ 12,500,000	^[32]
Investment cost		12,673,000	^[1],[31]	12,443,000	^[2],[32]
Investments at Fair Value		$ 12,408,000	^[31]	$ 12,443,000	^[32]
Drug Discovery & Development \| Senior Secured \| enGene, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-07		2025-07		2025-07		2025-07
Investment Interest Rate	^{[11],[27],[28]}			6.35%				6.35%
Investment, Basis Spread, Variable Rate		5.00%	^[7]	5.00%	^{[11],[27],[28]}	5.00%	^[7]	5.00%	^{[11],[27],[28]}
Investment, Interest Rate, Floor	^{[11],[27],[28]}			8.25%				8.25%
Interest Rate and Floor	^{[11],[27],[28]}			6.35%				6.35%
Principal Amount		$ 11,000,000	^{[17],[29],[30]}	$ 7,000,000	^[27],[28]
Investment cost		10,994,000	^{[1],[17],[29],[30]}	6,858,000	^{[2],[27],[28]}
Investments at Fair Value		$ 10,918,000	^{[17],[29],[30]}	$ 6,858,000	^[27],[28]
Drug Discovery & Development \| Senior Secured \| Finch Therapeutics Group, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-11				2026-11
Investment, Basis Spread, Variable Rate	^[7]	4.05%				4.05%
Investment, Interest Rate, Floor	^[7]	7.55%				7.55%
Principal Amount	^[10]	$ 15,000,000
Investment cost	^[1],[10]	14,958,000
Investments at Fair Value	^[10]	$ 14,241,000
Drug Discovery & Development \| Senior Secured \| G1 Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-11		2026-11		2026-11		2026-11
Investment Interest Rate	^[11],[27]			9.86%				9.86%
Investment, Basis Spread, Variable Rate		5.90%	^[7]	5.90%	^[11],[27]	5.90%	^[7]	5.90%	^[11],[27]
Investment, Interest Rate, Floor		9.15%	^[7]	9.15%	^[11],[27]	9.15%	^[7]	9.15%	^[11],[27]
Interest Rate and Floor	^[11],[27]			9.86%				9.86%
Principal Amount		$ 58,125,000	^{[10],[12],[18],[31]}	$ 58,125,000	^{[14],[15],[27],[32],[33]}
Investment cost		58,472,000	^{[1],[10],[12],[18],[31]}	57,873,000	^{[2],[14],[15],[27],[32],[33]}
Investments at Fair Value		$ 58,006,000	^{[10],[12],[18],[31]}	$ 57,874,000	^{[14],[15],[27],[32],[33]}
Drug Discovery & Development \| Senior Secured \| Geron Corporation \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2024-10		2024-10		2024-10		2024-10
Investment Interest Rate	^[11],[27]			6.55%				6.55%
Investment, Basis Spread, Variable Rate		5.75%	^[7]	5.75%	^[11],[27]	5.75%	^[7]	5.75%	^[11],[27]
Investment, Interest Rate, Floor		9.00%	^[7]	9.00%	^[11],[27]	9.00%	^[7]	9.00%	^[11],[27]
Interest Rate and Floor	^[11],[27]			6.55%				6.55%
Principal Amount		$ 18,500,000	^{[17],[18],[29]}	$ 32,500,000	^[27],[33]
Investment cost		19,003,000	^{[1],[17],[18],[29]}	32,704,000	^{[2],[27],[33]}
Investments at Fair Value		$ 19,059,000	^{[17],[18],[29]}	$ 32,744,000	^[27],[33]
Drug Discovery & Development \| Senior Secured \| Gritstone Bio, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2027-07				2027-07
Investment, Basis Spread, Variable Rate	^[7]	3.15%				3.15%
Investment, Interest Rate, Floor	^[7]	7.15%				7.15%
Investment, Interest Rate, Paid in Kind	^[7]	2.00%				2.00%
Principal Amount	^[9],[10]	$ 15,037,000
Investment cost	^[1],[9],[10]	14,989,000
Investments at Fair Value	^[9],[10]	$ 14,989,000
Drug Discovery & Development \| Senior Secured \| Hibercell, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-05		2025-05		2025-05		2025-05
Investment Interest Rate	^[11]			4.95%				4.95%
Investment, Basis Spread, Variable Rate		5.40%	^[7]	5.40%	^[11]	5.40%	^[7]	5.40%	^[11]
Investment, Interest Rate, Floor		8.65%	^[7]	8.65%	^[11]	8.65%	^[7]	8.65%	^[11]
Interest Rate and Floor	^[11]			4.95%				4.95%
Principal Amount		$ 17,000,000	^[17],[31]	$ 17,000,000	^[32]
Investment cost		17,244,000	^{[1],[17],[31]}	17,041,000	^[2],[32]
Investments at Fair Value		$ 17,225,000	^[17],[31]	$ 17,014,000	^[32]
Drug Discovery & Development \| Senior Secured \| HilleVax, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2027-05				2027-05
Investment, Basis Spread, Variable Rate	^[7]	1.05%				1.05%
Investment, Interest Rate, Floor	^[7]	4.55%				4.55%
Investment, Interest Rate, Paid in Kind	^[7]	2.85%				2.85%
Principal Amount	^{[9],[10],[31]}	$ 4,043,000
Investment cost	^{[1],[9],[10],[31]}	4,043,000
Investments at Fair Value	^{[9],[10],[31]}	$ 4,044,000
Drug Discovery & Development \| Senior Secured \| Iveric Bio Gene Therapy LLC \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2027-08				2027-08
Investment, Basis Spread, Variable Rate	^[7]	4.00%				4.00%
Investment, Interest Rate, Floor	^[7]	8.75%				8.75%
Principal Amount	^[10],[29]	$ 24,750,000
Investment cost	^{[1],[10],[29]}	24,530,000
Investments at Fair Value	^[10],[29]	$ 24,531,000
Drug Discovery & Development \| Senior Secured \| Humanigen, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date				2025-03				2025-03
Investment Interest Rate	^{[11],[26],[27]}			6.75%				6.75%
Investment, Basis Spread, Variable Rate	^{[11],[26],[27]}			5.50%				5.50%
Investment, Interest Rate, Floor	^{[11],[26],[27]}			8.75%				8.75%
Interest Rate and Floor	^{[11],[26],[27]}			6.75%				6.75%
Principal Amount	^[26],[27]			$ 20,000,000
Investment cost	^{[2],[26],[27]}			20,235,000
Investments at Fair Value	^[26],[27]			$ 19,985,000
Drug Discovery & Development \| Senior Secured \| Kaleido Biosciences, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date				2024-01				2024-01
Investment Interest Rate	^[11]			7.55%				7.55%
Investment, Basis Spread, Variable Rate	^[11]			6.10%				6.10%
Investment, Interest Rate, Floor	^[11]			9.35%				9.35%
Interest Rate and Floor	^[11]			7.55%				7.55%
Principal Amount	^[33]			$ 22,500,000
Investment cost	^[2],[33]			23,505,000
Investments at Fair Value	^[33]			$ 23,384,000
Drug Discovery & Development \| Senior Secured \| Locus Biosciences, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-07		2025-07		2025-07		2025-07
Investment Interest Rate	^[11]			4.95%				4.95%
Investment, Basis Spread, Variable Rate		6.10%	^[7]	6.10%	^[11]	6.10%	^[7]	6.10%	^[11]
Investment, Interest Rate, Floor		9.35%	^[7]	9.35%	^[11]	9.35%	^[7]	9.35%	^[11]
Interest Rate and Floor	^[11]			4.95%				4.95%
Principal Amount		$ 8,000,000	^[31]	$ 8,000,000	^[32]
Investment cost		8,084,000	^[1],[31]	7,977,000	^[2],[32]
Investments at Fair Value		$ 8,062,000	^[31]	$ 7,900,000	^[32]
Drug Discovery & Development \| Senior Secured \| Madrigal Pharmaceutical, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-05				2026-05
Investment, Basis Spread, Variable Rate	^[7]	3.95%				3.95%
Investment, Interest Rate, Floor	^[7]	7.45%				7.45%
Principal Amount	^[29]	$ 34,000,000
Investment cost	^[1],[29]	33,807,000
Investments at Fair Value	^[29]	$ 33,807,000
Drug Discovery & Development \| Senior Secured \| Phathom Pharmaceuticals, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-10		2026-10		2026-10		2026-10
Investment Interest Rate	^[11],[27]			7.50%				7.50%
Investment, Basis Spread, Variable Rate		2.25%	^[7]	2.25%	^[11],[27]	2.25%	^[7]	2.25%	^[11],[27]
Investment, Interest Rate, Floor		5.50%	^[7]	5.50%	^[11],[27]	5.50%	^[7]	5.50%	^[11],[27]
Investment, Interest Rate, Paid in Kind		3.35%	^[7]	3.35%	^[11],[27]	3.35%	^[7]	3.35%	^[11],[27]
Interest Rate and Floor	^[11],[27]			7.50%				7.50%
Principal Amount		$ 93,978,000	^{[9],[10],[18],[19],[29],[31]}	$ 87,116,000	^{[15],[20],[21],[27],[32],[33]}
Investment cost		93,948,000	^{[1],[9],[10],[18],[19],[29],[31]}	86,075,000	^{[2],[15],[20],[21],[27],[32],[33]}
Investments at Fair Value		$ 94,006,000	^{[9],[10],[18],[19],[29],[31]}	$ 86,075,000	^{[15],[20],[21],[27],[32],[33]}
Drug Discovery & Development \| Senior Secured \| Provention Bio, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-09				2026-09
Investment, Basis Spread, Variable Rate	^[7]	2.70%				2.70%
Investment, Interest Rate, Floor	^[7]	8.20%				8.20%
Principal Amount		$ 25,000,000
Investment cost	^[1]	24,552,000
Investments at Fair Value		$ 24,552,000
Drug Discovery & Development \| Senior Secured \| Redshift Bioanalytics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-01				2026-01
Investment, Basis Spread, Variable Rate	^[7]	4.25%				4.25%
Investment, Interest Rate, Floor	^[7]	7.50%				7.50%
Principal Amount	^[31]	$ 5,000,000
Investment cost	^[1],[31]	4,936,000
Investments at Fair Value	^[31]	$ 4,935,000
Drug Discovery & Development \| Senior Secured \| Scynexis, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-03		2025-03		2025-03		2025-03
Investment Interest Rate	^[11]			3.95%				3.95%
Investment, Basis Spread, Variable Rate		5.80%	^[7]	5.80%	^[11]	5.80%	^[7]	5.80%	^[11]
Investment, Interest Rate, Floor		9.05%	^[7]	9.05%	^[11]	9.05%	^[7]	9.05%	^[11]
Interest Rate and Floor	^[11]			3.95%				3.95%
Principal Amount		$ 18,667,000	^[17],[18]	$ 16,000,000
Investment cost		18,592,000	^{[1],[17],[18]}	15,826,000	^[2]
Investments at Fair Value		$ 18,524,000	^[17],[18]	$ 15,778,000
Drug Discovery & Development \| Senior Secured \| Seres Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2024-10		2023-11		2024-10		2023-11
Investment Interest Rate	^[11]			4.85%				4.85%
Investment, Basis Spread, Variable Rate		6.40%	^[7]	4.40%	^[11]	6.40%	^[7]	4.40%	^[11]
Investment, Interest Rate, Floor		9.65%	^[7]	9.65%	^[11]	9.65%	^[7]	9.65%	^[11]
Interest Rate and Floor	^[11]			4.85%				4.85%
Principal Amount		$ 37,500,000	^[17],[18]	$ 24,051,000
Investment cost		38,509,000	^{[1],[17],[18]}	24,777,000	^[2]
Investments at Fair Value		$ 38,657,000	^[17],[18]	$ 25,183,000
Drug Discovery & Development \| Senior Secured \| Syndax Pharmaceutics Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date				2024-04				2024-04
Investment Interest Rate	^[11]			4.99%				4.99%
Investment, Basis Spread, Variable Rate	^[11]			6.00%				6.00%
Investment, Interest Rate, Floor	^[11]			9.25%				9.25%
Interest Rate and Floor	^[11]			4.99%				4.99%
Principal Amount	^[15],[33]			$ 20,000,000
Investment cost	^{[2],[15],[33]}			20,646,000
Investments at Fair Value	^[15],[33]			$ 20,653,000
Drug Discovery & Development \| Senior Secured \| Tarsus Pharmaceuticals, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2027-02				2027-02
Investment, Basis Spread, Variable Rate	^[7]	5.20%				5.20%
Investment, Interest Rate, Floor	^[7]	8.45%				8.45%
Principal Amount	^{[10],[17],[29]}	$ 8,250,000
Investment cost	^{[1],[10],[17],[29]}	8,255,000
Investments at Fair Value	^{[10],[17],[29]}	$ 8,388,000
Drug Discovery & Development \| Senior Secured \| TG Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-01		2026-01		2026-01		2026-01
Investment Interest Rate	^[11],[27]			5.95%				5.95%
Investment, Basis Spread, Variable Rate		2.15%	^[7]	2.15%	^[11],[27]	2.15%	^[7]	2.15%	^[11],[27]
Investment, Interest Rate, Floor		5.40%	^[7]	5.40%	^[11],[27]	5.40%	^[7]	5.40%	^[11],[27]
Investment, Interest Rate, Paid in Kind	^[7]	3.45%				3.45%
Interest Rate and Floor	^[11],[27]			5.95%				5.95%
Principal Amount		$ 47,567,000	^{[9],[12],[18],[29]}	$ 51,450,000	^[27]
Investment cost		47,267,000	^{[1],[9],[12],[18],[29]}	50,470,000	^[2],[27]
Investments at Fair Value		$ 47,137,000	^{[9],[12],[18],[29]}	$ 50,470,000	^[27]
Drug Discovery & Development \| Senior Secured \| Uni Qure B V \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2025-12		2025-12		2025-12		2025-12
Investment Interest Rate	^{[11],[27],[28]}			7.28%				7.28%
Investment, Basis Spread, Variable Rate		4.70%	^[7]	4.70%	^{[11],[27],[28]}	4.70%	^[7]	4.70%	^{[11],[27],[28]}
Investment, Interest Rate, Floor		7.95%	^[7]	7.95%	^{[11],[27],[28]}	7.95%	^[7]	7.95%	^{[11],[27],[28]}
Interest Rate and Floor	^{[11],[27],[28]}			7.28%				7.28%
Principal Amount		$ 70,000,000	^{[12],[18],[19],[29],[30]}	$ 77,500,000	^{[14],[21],[27],[28],[33]}
Investment cost		72,015,000	^{[1],[12],[18],[19],[29],[30]}	78,755,000	^{[2],[14],[21],[27],[28],[33]}
Investments at Fair Value		$ 73,205,000	^{[12],[18],[19],[29],[30]}	$ 78,755,000	^{[14],[21],[27],[28],[33]}
Drug Discovery & Development \| Senior Secured \| Unity Biotechnology Inc \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2024-08		2024-08		2024-08		2024-08
Investment Interest Rate	^[11],[26]			6.25%				6.25%
Investment, Basis Spread, Variable Rate		6.10%	^[7]	6.10%	^[11],[26]	6.10%	^[7]	6.10%	^[11],[26]
Investment, Interest Rate, Floor		9.35%	^[7]	9.35%	^[11],[26]	9.35%	^[7]	9.35%	^[11],[26]
Interest Rate and Floor	^[11],[26]			6.25%				6.25%
Principal Amount		$ 20,000,000	^[17]	$ 22,701,000	^[26]
Investment cost		20,990,000	^[1],[17]	23,293,000	^[2],[26]
Investments at Fair Value		$ 20,844,000	^[17]	$ 23,627,000	^[26]
Drug Discovery & Development \| Senior Secured \| Valo Health L L C \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2024-05		2024-05		2024-05		2024-05
Investment Interest Rate	^[11]			3.85%				3.85%
Investment, Basis Spread, Variable Rate		6.45%	^[7]	6.45%	^[11]	6.45%	^[7]	6.45%	^[11]
Investment, Interest Rate, Floor		9.70%	^[7]	9.70%	^[11]	9.70%	^[7]	9.70%	^[11]
Interest Rate and Floor	^[11]			3.85%				3.85%
Principal Amount		$ 9,583,000	^[12],[17]	$ 11,500,000	^[14]
Investment cost		9,805,000	^{[1],[12],[17]}	11,547,000	^[2],[14]
Investments at Fair Value		$ 9,760,000	^[12],[17]	$ 11,492,000	^[14]
Drug Discovery & Development \| Senior Secured \| Viridian Therapeutics Inc \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2026-10				2026-10
Investment, Basis Spread, Variable Rate	^[7]	4.20%				4.20%
Investment, Interest Rate, Floor	^[7]	7.45%				7.45%
Principal Amount	^{[10],[17],[29]}	$ 2,000,000
Investment cost	^{[1],[10],[17],[29]}	2,004,000
Investments at Fair Value	^{[10],[17],[29]}	$ 1,969,000
Drug Discovery & Development \| Senior Secured \| X Four Pharmaceuticals Inc \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date		2024-07		2024-07		2024-07		2024-07
Investment Interest Rate	^[11]			8.80%				8.80%
Investment, Basis Spread, Variable Rate		3.75%	^[7]	3.75%	^[11]	3.75%	^[7]	3.75%	^[11]
Investment, Interest Rate, Floor		8.75%	^[7]	8.75%	^[11]	8.75%	^[7]	8.75%	^[11]
Interest Rate and Floor	^[11]			8.80%				8.80%
Principal Amount		$ 32,500,000	^{[12],[17],[18]}	$ 32,500,000	^[14],[33]
Investment cost		33,464,000	^{[1],[12],[17],[18]}	34,140,000	^{[2],[14],[33]}
Investments at Fair Value		$ 33,291,000	^{[12],[17],[18]}	$ 34,085,000	^[14],[33]
Drug Discovery & Development \| Senior Secured \| Yumanity Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date				2024-01				2024-01
Investment Interest Rate	^[11]			5.92%				5.92%
Investment, Basis Spread, Variable Rate	^[11]			4.00%				4.00%
Investment, Interest Rate, Floor	^[11]			8.75%				8.75%
Interest Rate and Floor	^[11]			5.92%				5.92%
Principal Amount				$ 12,732,000
Investment cost	^[2]			13,256,000
Investments at Fair Value				$ 13,187,000
Drug Discovery & Development \| Senior Secured \| Center for Breakthrough Medicines Holdings, LLC [Member] \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Maturity Date				2023-05				2023-05
Investment Interest Rate	^[11]			7.50%				7.50%
Investment, Basis Spread, Variable Rate	^[11]			5.50%				5.50%
Investment, Interest Rate, Floor	^[11]			8.75%				8.75%
Interest Rate and Floor	^[11]			7.50%				7.50%
Principal Amount				$ 5,000,000
Investment cost	^[4]			5,005,000
Investments at Fair Value				$ 5,005,000
Drug Discovery & Development \| Senior Secured \| Floor Rate \| enGene, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment, Interest Rate, Floor	^[7]	8.25%				8.25%
Drug Discovery & Development \| Senior Secured \| Exit Fee \| Chemocentryx, Inc. \| Debt Investments Under 1 Year Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	6.25%				6.25%
Interest Rate and Floor	^[7]	6.25%				6.25%
Drug Discovery & Development \| Senior Secured \| Exit Fee \| Chemocentryx, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	7.15%				7.15%
Interest Rate and Floor	^[7]	7.15%				7.15%
Drug Discovery & Development \| Senior Secured \| Exit Fee \| Nabriva Therapeutics \| Debt Investments Under 1 Year Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	9.95%				9.95%
Interest Rate and Floor	^[7]	9.95%				9.95%
Drug Discovery & Development \| Senior Secured \| Exit Fee \| Akero Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	5.85%				5.85%
Interest Rate and Floor	^[7]	5.85%				5.85%
Drug Discovery & Development \| Senior Secured \| Exit Fee \| Alladapt Immunotherapeutics Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	5.30%				5.30%
Interest Rate and Floor	^[7]	5.30%				5.30%
Drug Discovery & Development \| Senior Secured \| Exit Fee \| Aldeyra Therapeutics, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	6.95%				6.95%
Interest Rate and Floor	^[7]	6.95%				6.95%
Drug Discovery & Development \| Senior Secured \| Exit Fee \| Applied Genetic Technologies Corporation \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate		6.95%	^[7]	6.95%	^[11]	6.95%	^[7]	6.95%	^[11]
Interest Rate and Floor		6.95%	^[7]	6.95%	^[11]	6.95%	^[7]	6.95%	^[11]
Drug Discovery & Development \| Senior Secured \| Exit Fee \| ATAI Life Sciences N.V. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate	^[7]	6.95%				6.95%
Interest Rate and Floor	^[7]	6.95%				6.95%
Drug Discovery & Development \| Senior Secured \| Exit Fee \| Aveo Pharmaceuticals, Inc. \| Debt Investments 1-5 Years Maturity
Investment Holdings [Line Items]
Investment Interest Rate		6.95%	^[7]	6.95%	^[11]	6.95%	^[7]	6.95%	^[11]